It's Time to Start Selling

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Taking on extra risk has been a very profitable move over the past couple of years. Since the beginning of March 2009, the S&P 500 is up 92% and the Russell 2000 is up 129%. Investors have more or less been pushed into riskier assets by the Federal Reserve as its low interest rates make lower-risk investments unpalatable.

But how long will the "risk-on trade" last? Not much longer, according to GMO's Jeremy Grantham.

Well ... maybe a little while longer
Grantham starts out his most recent quarterly letter with an extensive review of times in the past when financial markets got particularly wacky -- U.S. small caps in 1974, Japanese stocks in 1989, U.S. stocks in 2000, U.S. housing in 2007, and so on. Notably, while he saw the reversals of those crazy times ahead of most, he pokes himself for generally being too early in reacting to them.

And yet he's ready to potentially be early on another call: getting out of U.S. stocks right now.

With a rash of factors cropping up to conspire against the global economy -- the earthquake in Japan, unrest in the Middle East, etc -- Grantham is concerned that without a "QE3" (a third round of quantitative easing by the Fed), riskier assets are a dicey proposition. As he puts it: "Risk now should be more reflective of an investment world that has stocks selling at 40% over fair value (about 920 on the S&P 500) and fixed income, manipulated by the Fed, also badly overpriced."

The GMO move
In his letter, Grantham gives a pretty clear outline of what he thinks investors should be doing in this environment:

Investors should take a hard-nosed value approach, which at GMO means having substantial cash reserves around a base of high quality blue chips and emerging market equities, both of which have semi-respectable real imputed returns of over 4% real on our 7-year forecast. The GMO position has also taken a few more percentage points of equity risk off the table.

While GMO hasn't filed its SEC paperwork disclosing its first-quarter holdings yet, we can get some idea of what Grantham views as attractive blue-chip and emerging market stocks by looking at what GMO was holding at the end of last year. As far as general blue chips, GMO's major positions included Oracle, Pfizer (NYSE: PFE  ) , Apple (Nasdaq: AAPL  ) , and ExxonMobil. Emerging markets holdings included Russia's JSC Gazprom and LUKOIL, Brazil's Vale (NYSE: VALE  ) and Petrobras (NYSE: PBR  ) , and Thailand's PTT Public. The portfolio also includes major multinationals like Philip Morris International (NYSE: PM  ) that aren't based in an emerging-market country but do a significant amount of business in those countries.

Obviously those positions may have changed since the last report, but large-cap blue chips have been a focus for Grantham for a while now, so it should give a general idea of what he views as the types of blue chips that investors should be focusing the portion of their invested portfolio on. That said, as far as Grantham is concerned, the move right now isn't loading up on stocks -- blue chip or not -- but rather holding onto some higher-quality positions while trimming the invested portion of your portfolio overall.

Run! Or, run?
Unfortunately, I find myself nodding along with Grantham. Broadly, the stock market looks far from cheap and small caps in particular look pricey.

However, those that have stumbled on my articles in the past know that my investing tends to be focused on buying high-quality companies paying solid dividends at reasonable prices and then (trying!) to practice patience. That meshes with Grantham's favorable view of higher-quality companies, but also means that I'm in no rush to sell the stocks that I do hold.

As far as keeping cash on the sidelines, this approach generally has a natural mechanism for increasing your cash holdings -- as stock prices rise, dividend yields fall and valuations go up, so there are simply fewer attractive stocks to buy.

That said, I -- and I'm assuming most reading this -- am not in nearly the same situation as Jeremy Grantham. At GMO, he has more than $100 billion that needs allocating, so when the number of attractive opportunities starts to fall at all, his options become a lot more limited. Since I have considerably less than $100 billion that needs to be put to work, I can still find a good number of opportunities today as long as I'm a little choosy.

And "choosy" is the operative word. Even among companies with similar metrics, valuations can vary widely. All of the stocks below have Buffett ratios (a measure similar to return on capital) between 25% and 35% and expected long-term growth between 10% and 20%, but their valuations are all over the board.


Buffett Ratio

Expected Long-Term Growth

Forward Price-to-Earnings Ratio

Intel (Nasdaq: INTC  )




Gilead Sciences (Nasdaq: GILD  )








Idexx Laboratories








Blue Nile




Source: Capital IQ, a Standard & Poor's company.

The believability of the growth estimates may account for some of the valuation discrepancy and some of these companies -- Motley Fool Rule Breakers recommendation Blue Nile, for instance -- regularly report cash flow well in excess of their net income. However, I think the table underscores the fact that the market is far from homogenous and there are still value opportunities out there.

Over the horizon
Of course while I tend to focus on large, blue-chip equities because that's where I see value, I wouldn't want to short-change Grantham by skipping over his longer-term recommendation, which is resource plays and "stuff in the ground" generally. That shouldn't be all that surprising considering the number of resource-focused stocks among his big holdings (Exxon, Vale, Petrobas, LUKOIL, etc).

And if you're on board with this part of his outlook, you may want to check out the special report "3 Stocks for $100 Oil." You can access the report absolutely free by clicking here.

Intel and Pfizer are Motley Fool Inside Value choices. Blue Nile is a Motley Fool Rule Breakers selection. Apple and Gilead Sciences are Motley Fool Stock Advisor recommendations. Philip Morris International is a Motley Fool Global Gains selection. Intel and Petroleo Brasileiro are Motley Fool Income Investor choices. The Fool owns shares of and has bought calls on Intel. Motley Fool Options has recommended a bull call spread position on Apple. Motley Fool Options has recommended a diagonal call position on Intel. The Fool owns shares of Apple, ExxonMobil, Oracle, Petroleo Brasileiro, and Philip Morris International. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insights makes us better investors.

Fool contributor Matt Koppenheffer owns shares of Philip Morris International and Intel, but does not have a financial interest in any of the other companies mentioned. You can check out what Matt is keeping an eye on by visiting his CAPS portfolio, or you can follow Matt on Twitter @KoppTheFool or on his RSS feed. The Fool's disclosure policy prefers dividends over a sharp stick in the eye.

Read/Post Comments (11) | Recommend This Article (32)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On May 13, 2011, at 9:24 PM, trenton1ryan wrote:

    PM and INTC for sure. The others (maybe XOM), I'll pass at this time.

  • Report this Comment On May 13, 2011, at 10:01 PM, TruffelPig wrote:

    The economy will start kicking and the stocks will go higher. There is really no choice. Otherwise Asia will completely take over the world economy.

  • Report this Comment On May 15, 2011, at 5:21 PM, antigo83 wrote:

    Wow, scary headline, and tomorrow the title of his blog will be........Time To Buy. This sight just helps you supply Wall Street and drain your cash flow.

  • Report this Comment On May 15, 2011, at 5:25 PM, antigo83 wrote:

    Become your own banker. Quit lining the pockets of the lying, cheating, deregulating politicians and banking whores who put our country into the position it is now in.

  • Report this Comment On May 15, 2011, at 6:17 PM, GregLoire wrote:

    I thought The Motley Fool was all about rational, long-term investing... but now we're trying to speculatively time the market? How many people have a good track record of doing this?

  • Report this Comment On May 16, 2011, at 12:19 AM, mdickson99 wrote:

    This article is off topic to the sites general content. Telling people what and when to buy sell is being a financial adviser. Let them do it and stick to articles more inline with the community.


  • Report this Comment On May 16, 2011, at 10:36 AM, pebbles444 wrote:

    So....should we be selling everything or what? Is the S&P going back down to the 900 range?

  • Report this Comment On May 16, 2011, at 2:04 PM, pebbles444 wrote:

    Since you're clearly indicating that it's time to sell, could you please indicate whenever it's time to buy back in?

  • Report this Comment On May 20, 2011, at 12:10 PM, ddepperman wrote:

    The market has had 3 big dips in the last 6 months or so. Does it matter whether you sell off before the drop, or right after? Perhaps the fear is that the drop will be so great so fast that you can't catch it.

    That's a valid fear.

    Might be good to put stop loss orders on your holdings and inch them higher if the market still climbs.

  • Report this Comment On May 20, 2011, at 11:23 PM, Fusileer wrote:

    OK! I'm selling it all and holding just cash. I guess at this point, there is no sense in logging on to Fool anymore. Bu bye now.

    ...............................................................................Is this really what you're advocating? Of course with the U.S. debt ceiling being hit, the jerks in Congress and the arrogent King of all Jerks in the Oval office, these are scary and unpredictable times.

  • Report this Comment On May 24, 2011, at 9:44 PM, hachmujt wrote:

    I have to agree with the majority of the comments. I have been reading too much market timing stuff around the Fool. Bad advice in my book. 13 year fool here.

    The stock ideas in the article are not the problem.

    Just buy a little bit every month and hold it forever.

    This article has 30 recs, how many would have hit the no-rec button?

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1494501, ~/Articles/ArticleHandler.aspx, 10/26/2016 11:21:05 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,217.27 48.00 0.26%
S&P 500 2,144.66 1.50 0.07%
NASD 5,277.81 -5.59 -0.11%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/26/2016 11:05 AM
AAPL $115.09 Down -3.17 -2.68%
Apple CAPS Rating: ****
GILD $75.71 Up +1.30 +1.74%
Gilead Sciences CAPS Rating: *****
INTC $35.17 Up +0.07 +0.20%
Intel CAPS Rating: ****
PBR $12.34 Up +0.16 +1.27%
Petroleo Brasileir… CAPS Rating: **
PFE $32.47 Up +0.19 +0.59%
Pfizer CAPS Rating: ****
PM $96.12 Down -0.47 -0.48%
Philip Morris Inte… CAPS Rating: ****
VALE $6.75 Down -0.04 -0.59%
Companhia Vale CAPS Rating: ****